Last reviewed · How we verify

NCT06998355

BE.Amycon Registry UZ Leuven

Suspended Last updated 28 August 2025
What this trial tests

trial testing Registry in Amyloidosis in 550 participants. Suspended.

Timeline
1 September 2025
Primary endpoint
31 December 2027
1 June 2028

Quick facts

Lead sponsorUniversitaire Ziekenhuizen KU Leuven
StatusSuspended
Study typeOBSERVATIONAL
Enrollment550
Start date1 September 2025
Primary completion31 December 2027
Estimated completion1 June 2028
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

18 and older, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to establish database with (limited) personal and health data of patients diagnosed with amyloidosis (any subtype) in order to get better insights on the disease presentation, disease evolution pattern, treatment plans and responses and survival.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Registry

Trials testing the same drug.

Other recruiting trials for Amyloidosis

Currently open trials in the same condition.

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06998355.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing